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Abstract
Background: Birt-Hogg-Dubé (BHD) syndrome is a rare inherited autosomal genodermatosis and caused by
germline mutation of the folliculin (FLCN) gene, a tumor suppressor gene of which protein product is involved in
mechanistic target of rapamycin (mTOR) signaling pathway regulating cell growth and metabolism. Clinical
manifestations in BHD syndrome is characterized by fibrofolliculomas of the skin, pulmonary cysts with or without
spontaneous pneumothorax, and renal neoplasms. There has been no pulmonary neoplasm reported in BHD
syndrome, although the condition is due to deleterious sequence variants in a tumor suppressor gene. Here we
report, for the first time to our knowledge, a patient with BHD syndrome who was complicated with a clear cell
“sugar” tumor (CCST) of the lung, a benign tumor belonging to perivascular epithelioid cell tumors (PEComas) with
frequent causative relation to tuberous sclerosis complex 1 (TSC1) or 2 (TSC2) gene.
Case presentation: In a 38-year-old Asian woman, two well-circumscribed nodules in the left lung and multiple
thin-walled, irregularly shaped cysts on the basal and medial area of the lungs were disclosed by chest
roentgenogram and computer-assisted tomography (CT) during a preoperative survey for a bilateral faucial
tonsillectomy. Analysis of the resected tumor showed large polygonal cells with clear cytoplasm proliferating in a
solid pattern. Immunohistochemistry revealed that these tumor cells were positive for microphthalmia-transcription
factor, S100, and CD1a but negative for HMB45, indicating that the tumor was a CCST. Genetic testing indicated
that the patient had a germline mutation on exon 12 of the FLCN gene, i.e., insertion of 7 nucleotides (CCACCCT)
(c.1347_1353dupCCACCCT). Direct sequencing of the FLCN exon 12 using genomic DNA obtained from her
microdissected CCST cells clearly revealed loss of the wild-type FLCN sequence, which confirmed complete
functional loss of the FLCN gene. On the other hand, no loss of heterozygosity around TCS1- or TSC2-associated
genetic region was demonstrated.
Conclusion: To our knowledge, this is the first report of CCST of the lung in a patient with BHDS, indicating that
CCST should be added to the spectrum of pulmonary manifestations of BHDS.
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Background
Birt-Hogg-Dubé (BHD) syndrome is a rare inherited auto-
somal genodermatosis originally reported by Hornstein and
Knickenberg in 1975 [1] and by three Canadian doctors
(Birt, Hogg, and Dubé) in 1977 [2]. BHD syndrome is
caused by mutations of the FLCN gene, which codes a pro-
tein called folliculin and functions as a tumor suppressor
gene [3, 4]. Several tumor-suppressor genes are linked to
hamartoma syndromes through the convergent energy/nu-
trient-sensing pathways involved in the mechanistic target
of rapamycin (mTOR) signaling, especially mTOR complex-
1 (mTORC1) [5–7]: TSC1 and TSC2 being responsible for
tuberous sclerosis complex (TSC) [8], LKB1 for Peutz-
Jeghers syndrome [9], and PTEN for Cowden syndrome
[10]. Since mTORC1 is strongly related to cell growth, pro-
liferation, and metabolism, hamartoma syndromes are char-
acterized by an increased risk of the development of benign
as well as malignant neoplasms. BHD syndrome is one such
hamartoma syndrome. Recent studies have shown the close
association of folliculin with the mTORC1 signaling path-
way; folliculin acts as a GTPase-activating-protein for RagC/
D to recruit mTORC1 to lysosomes where mTORC1 exerts
its function [11]. Accordingly, patients with BHD syndrome
are at risk of developing neoplasms in skin (fibrofollicu-
loma) and kidneys (renal cell carcinoma), colon carcin-
oma, or other tumors. However, no pulmonary tumor
associated with BHD syndrome has been reported to date.
Clear cell “sugar” tumor (CCST) of the lung is a rare
benign tumor originally reported in 1971 by Liebow and
Castleman, who noted its resemblance to metastases of
clear renal cell carcinomas [12]. CCSTs belong to a fam-
ily of perivascular epithelioid cell tumors (PEComas) that
are defined by their morphologically and immunohisto-
chemically distinctive perivascular epithelioid vascular cells
and arise at a variety of visceral and soft tissue sites [13].
PEComas include angiomyolipomas [14] and lymphangio-
leiomyomatosis [15], both being the representative disor-
ders related to TSC. Actually, the genetic and molecular
bases of PEComas appear to be aberrations on chromo-
some 16 and at the TSC2 locus resulting in activation of
the mTOR pathway [16].
We herein describe a patient with BHD syndrome who
developed CCST of the lung. We demonstrated that this
patient’s CCST entailed complete functional loss of FLCN
without TSC2 loss of heterozygosity (LOH), supporting
the presumption that TSC1/2 and FLCN share the mech-
anism for their tumorigenesis.
Case presentation
A solitary pulmonary nodule measuring 25 mm in diam-
eter was found in the left lung of a 38-year-old female
whose chest roentgenogram (Fig. 1a) underwent preopera-
tive assessment in January 2006 during preparation for a
bilateral faucial tonsillectomy due to recurrent tonsil-
litis. The computer-assisted tomography (CT) of the
chest showed two well-circumscribed nodules (approxi-
mately 25 and 5 mm in diameter, respectively) without
apparent contrast enhancement in the lower, left lobe
(Fig. 1b and c). In addition to the nodules, multiple
thin-walled, irregularly shaped cysts were distributed
A B
C
Fig. 1 Plain radiograph and computed tomography of the chest. Plain chest radiograph on admission showed a nodular shadow superimposed
on the edge of a cardiac silhouette (a). Computed tomography of the chest demonstrated a round nodule (the larger nodule, 25 mm in
diameter) with a clear margin in the lower, left lobe and multiple irregularly shaped cysts in the bilateral lower lobes (b). Another axial image
showed a smaller nodule (5 mm in diameter) having a similar characteristics with the larger nodule (c). Note that a small cyst abutting a
pulmonary artery (white arrowheads)
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predominantly on the basal and medial areas of the
lungs (Fig. 1b and c). She was asymptomatic, and phys-
ical examinations found no abnormalities. She was an
ex-smoker but to the very mild degree of 0.6 pack-year.
However, her past medical history was remarkable. Vocal
cord nodules were resected when she was 25-, 26-, and 27-
years-old; three episodes of spontaneous pneumothorax
(PTX) occurred at the ages of 26, 27, and 30 years (chest
tube drainage for left PTX at 26-years-old, and operations
were performed for a right PTX at 27- and for left PTX at
30-years-old). The resection of multiple uterine myomas
followed when she reached 30 years of age, and the left-
sided thyroid gland was extirpated to remove a well-
differentiated papillary adenocarcinoma when she was 32-
years-old. The family history taken from interviews with
the patient and her mother was extraordinary in terms of
PTX events and neoplasms (Fig. 2). Her mother (III-2 in
Fig. 2) had experienced spontaneous PTX and renal cancer
(no detailed information on histological type), and the ma-
ternal grandmother (II-2 in Fig. 2) had undergone a spon-
taneous PTX. Fibrofollicuoma-like papules were noted on
faces and necks of both the patient (IV-1 in Fig. 2) and her
mother, but were not mentioned for any other family
members during their interviews. Later, we confirmed by
CT of the chest that the mother had multiple pulmonary
cysts with characteristic features similar to those of the
index case.
For the patient described here, a CT-guided needle biopsy
of the left pulmonary nodule (the larger nodule) was per-
formed to determine a diagnosis. Pathological examination
revealed that it was a clear cell carcinoma of undetermined
origin. No clear cell carcinoma of the kidney was identified
by magnetic resonance imaging. Ultrasonography of the
thyroid gland showed no abnormalities. Subsequently, on
February 28, 2006, a left lower lobectomy was performed.
The left hilar lymph node was negative for metastasis, and
no further resection of mediastinal lymph nodes was per-
formed. Neither recurrence nor metastasis has been found
since then or up to the writing of this case report in 2015.
Materials and methods
Histopathologic and immunohistochemical examinations
The patient’s resected lung tissues were fixed in 10% buff-
ered formalin, embedded in paraffin after routine pro-
cessing, and stained with hematoxylin and eosin (H&E).
Immunostaining was performed with antibodies directed
to the following: vimentin (dilution 1:400, Dako Cytoma-
tion, Carpinteria, CA, USA), cytokeratin (dilution 1:200,
Immunotech, Malseille, France), α-smooth muscle actin
(α-SMA) (dilution 1:200, Dako Cytomation), HMB45 (di-
lution 1:200, Dako Cytomation), Melan-A (dilution 1:50,
Dako Cytomation), PNL-2 (dilution 1:200, Dako Cyto-
mation), microphthalmia-associated transcription fac-
tor (dilution 1:50, Leica Biosystems, New Castle, UK),
S100 (dilution 1:300, Dako Cytomation), CD1a (dilution
1:100, Dako Cytomation, clone O10), CD10 (dilution
1:100, Dako Cytomation), CD63 (dilution 1:400, Chemi-
con, Temecula, CA, USA), and folliculin (dilution 1:150,
Santa Cruz, Paso Robles, CA, USA). An EnVision Dual
LINK system-HRP (a polymer-based detection system,
Dako Cytomation) was used to detect binding of the first
antibodies according to the manufacturer’s instructions,
Fig. 2 The family pedigree. The family pedigree includes a symbolic presentation of the three clinical features of Birt-Hogg-Dubé (BHD) syndrome:
pneumothorax, fibrofolliculoma-like papules (not proven by biopsy), and renal cancer. The Roman numerals at the left side represent generations.
FLCN genetic testing was performed in the index case (IV-1, arrow) and her mother (III-2), and both were demonstrated to carry the germline FLCN
mutation [indicated by E+(FLCN)]. A marked prevalence of cancer-related death was found among maternal first- and second-generation descendants.
The index case and mother also had a past medical history of malignancy (as described in the text)
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and 3, 3′-diaminobenzidine tetrahydrochloride was used
as the chromogen.
Mutation analysis of the FLCN gene and LOH analysis of
the FLCN gene-associated region
Genomic DNA isolated from peripheral blood leukocytes
was utilized to identify a germline FLCN mutation accord-
ing to the method described previously [17]. Briefly, each
exon of the FLCN gene was separately amplified and then
screened by denaturing high-performance liquid chroma-
tography. When a mobility shift was detected, sequencing
of the exon of concern was performed using an automated
sequencer (ABI Prism BigDye Terminator v1.1 Cycle Se-
quencing kit and ABI 3130 Genetic Analyzer; both Ap-
plied Biosystems, Foster City, CA, USA). Cloning of the
PCR product was performed using a TA cloning kit (Invi-
trogen TM, Houston, TX, USA).
For LOH analysis of the FLCN gene-associated region
(chromosome 17p12.2), tumor cells in a lung nodule were
manually microdissected from an 8-μm-thick pathological
specimen under an inverted microscope. Normal alveolar
tissues were also microdissected as a control. Genomic
DNA was extracted from the microdissected cells with
25 μl extraction buffer consisting of 50 mM Tris–HCl
(pH8.0), 1 mM EDTA, 0.5% Tween 20, and 1/50 volume of
proteinase K solution (10 mg/ml). Two microsatellite
markers, D17S740 and D17S2196, were examined for LOH
analysis according to the method described by Khoo et al.
[18]; the FLCN gene is located on the genome between
these two markers. The PCR products were electropho-
resed using an Applied Biosystems 3130/3130xl Genetic
Analyzer. LOH analysis was performed using Gene Map-
per® 4.0 (both from Applied Biosystems, Foster City, CA,
USA). To confirm reproducibility, all lesions were exam-
ined at least twice. A reduction in signal intensity over 50%
was defined as LOH.
Results
Pathologic findings in pulmonary nodules
The two tumors, measuring 25 mm and 5 mm in diameter,
respectively, were clearly demarcated from lung paren-
chyma. They showed identical histopathological findings
and consisted of large polygonal cells with clear cytoplasm
in a solid pattern (Fig. 3a). A meshwork-like vasculature
separated these tumor cells, some of which were small with
round nuclei but others of larger size contained bizarre nu-
clei without hyperchromaticity. The cytoplasm stained
readily with periodic acid-Schiff (PAS) (Fig. 3b), but neither
mitosis nor vascular invasion was seen. Although the pre-
operative diagnosis was clear cell carcinoma of undeter-
mined origin, that designation was then corrected to clear
cell “sugar” tumor (CCST) of the lung, belonging to a fam-
ily of PEComa [19]. The results of immunohistochemistry
are summarized in Table 1. Analysis revealed that the
tumor cells were immunopositive for vimentin, micro-
phthalmia transcription factor (Fig. 3c), S100, CD1a
(Fig. 3d), CD10 (Fig. 3e), CD63, and folliculin (Fig. 3f), but
immunonegative for cytokeratin, α-smooth muscle actin,
HMB45, Melan-A, and PNL-2. Interestingly, immunoposi-
tivity for folliculin was stronger in the cytoplasm of large
tumor cells with bizarre nuclei than in that of the small
tumor cells with round nuclei (Fig. 3f). Additionally, there
was no proliferation of lymphangioleiomyomatosis cells ob-
served in the underlying lung parenchyma.
Genetic diagnosis of BHD syndrome and LOH analysis
Family history of pulmonary cysts/spontaneous PTX and
renal tumors as well as characteristic radiologic features
was strongly suggestive of BHD syndrome and prompted
us to perform FLCN genetic testing. Mutation analysis
identified a germline mutation on exon 12 of the FLCN
gene, an insertion of 7 nucleotides (CCACCCT) (c.
c.1347_1353dupCCACCCT) (Fig. 4). The expected re-
sult would be a frame shift and premature termination
of protein translation [p.(Val452Profs*457)], thereby es-
tablishing the diagnosis of BHD syndrome.
CCST showed LOH at both D17S740 and D17S2196
(Fig. 5). Direct sequencing of exon 12 using genomic DNA
obtained from the patient’s microdissected CCSTcells (from
the larger tumor) clearly revealed the loss of wild-type
FCLN sequence (Fig. 4c), confirming the complete loss-of-
function of the FLCN gene (Knudson’s 2-hit theory). In con-
trast, none of the microsatellite markers on two TSC loci
(TSC1 on chromosome 9q and TSC2 on chromosome 16)
manifested LOH (data not shown).
Discussion
Our study reports, for the first time, a CCST of the lung in
a patient with BHD syndrome. Additionally, no pulmonary
neoplasm has been reported to date that was proved to have
complete loss-of-function type FLCNmutation, hence meet-
ing the Knudson’s 2-hit theory. CCST of the lung belongs to
a family of PEComas that is characterized by perivascular
epithelioid cell differentiation and immunopositivity for both
myoid and melanocytic immunohistochemical markers; a
representative of the latter is HMB45. These immunohisto-
chemical profiles are adjunctively important to differ-
entiate CCST from renal cell carcinoma. However, the
existence of HMB45-negative PEComas was reported
[20–23]. We examined the expression of four different
markers of the melanocytic lineage (HMB45, Melan-A,
PNL-2, and microphthalmia-associated transcription fac-
tor) in our patient and found that, of those markers, only
microphthalmia-associated transcription factor was immu-
nopositive. Accordingly, based on both morphological ap-
pearance and immunohistochemical features, we diagnosed
this patient with HMB45-negative CCST of the lung.
Gunji-Niitsu et al. BMC Medical Genetics  (2016) 17:85 Page 4 of 8
This is the first example described that associates the de-
velopment of CCST with functional loss of FLCN. Interest-
ingly, this woman’s test results document a stronger
immunopositivity for folliculin in the cytoplasm of large
tumor cells with bizarre nuclei than in that of small tumor
cells with round nuclei. Still unclear is whether the immu-
noreactivity we detected for polyclonal anti-folliculin anti-
body implies a causative role of mutated folliculin in the
tumorigenesis of CCST or merely nonspecific binding. As
is well-known, the development of PEComas is closely as-
sociated with dysregulated mTORC1 activity, which is
often due to a functional loss of TSC1 or TSC2. Although
the function of folliculin is not fully understood, folliculin
and mTORC1 are considered to be functionally related in
the cellular signaling pathway; i.e., folliculin acts as a
GTPase-activating-protein for RagC/D for the recruitment
of mTORC1 to lysosomes, where mTORC1 exerts its
function [11, 24]. Recently, a distinct subset of PEComas
was reported to harbor a TFE3 gene fusion [20]. Interest-
ingly, these tumors are immunopositive for TFE3, but
negative for markers of the melanocyte lineage, such as
Table 1 Summary of immunoreactivity demonstrated in Birt-




Vimentin + (Focally strong)




Microphthalmia transcription factor +
S100 + (Focally strong)
CD1a + (Focally weak)
CD10 + (Focally strong)
CD63 + (Diffusely weak)
folliclin + (Focally strong)
Fig. 3 Pathologic findings of a pulmonary nodule in the left lower lobe. The nodule consisted of polygonal tumor cells with pleomorphic nuclei
and clear cytoplasm (a, H&E). The PAS stain was intensively positive in cytoplasm of tumor cells (b). Immunohistochemistry revealed that nuclei of
the tumor cells were diffusely positive for microphthalmia transcription factor (c), and their membrane was weakly positive for CD1a (d), strongly
positive for CD10 (e), and focally positive for folliculin (f)
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microphthalmia-associated transcription factor, Mart-1,
and HMB45. The CCST in our patient showed no immu-
noreactivity for TFE3 (data not shown). Variability of im-
munostaining results regarding cell-lineage markers may
be related to the uncertainty of CCST’s cellular origin [19].
However, the CCST described here showed membranous
immunopositivity for CD1a, a useful marker for Langer-
hans cells, as Adachi et al. previously reported [25].
Clinically notable in the family of our patient are the
many deaths from cancer in the maternal ancestors (Fig. 2).
Multiple occurrences of neoplasms at various sites includ-
ing uterus, thyroid, vocal cord, and the lung in the index
case are also remarkable. Although FLCN is considered to
function as a tumor-suppressor gene, the established pro-
pensity for cancer in BHD syndrome so far is limited to the
renal neoplasms [26–28]; whether BHD syndrome confers
the risk of developing colorectal cancer remains conjectural
[29]. We previously reported that the de novo FLCN muta-
tion occurred in descendents of patients with familial
adenomatous polyposis [30], a disease caused by germ-
line mutation of the APC gene. Historically, BHD syn-
drome was first identified in a family who developed
hereditary medullary carcinoma of the thyroid, a disease
now recognized as a tumor-suppressor gene syndrome
Fig. 4 Mutation analysis of the FLCN gene. Sequencing of exon 12 of the FLCN gene demonstrated a superimposed sequence after the CCACCCT
repeat when genomic DNA isolated from the index case’s peripheral blood leukocytes was used as a template (a). Cloning of the PCR product of
exon 12 identified clones carrying the wild-type sequence and those carrying an insertion of 7 nucleotides (CCACCCT) (c.1347_1353dupCCACCCT),
resulting in a frame shift and premature termination of protein translation (b). In contrast, only the mutated sequence with a 7-nucleotide insertion
was demonstrated when genomic DNA isolated from microdissected tumor cells was utilized as a template (c)
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caused by a germline RET mutation [2]. In this context,
the present family may represent a de novo FLCN muta-
tion that emerged in the patient’s mother and grand-
mother who may have descended from a family with an
unknown cancer propensity.
Conclusions
To our knowledge, this is the first report of CCST of the
lung in a patient with BHD syndrome and may suggest
that folliculin and mTORC1 are closely associated with
the tumorigenesis of this rare affliction.
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Fig. 5 Results of loss-of-heterozygosity (LOH) analysis. Representative results of LOH analysis at D17S2196 and D17S740. Genomic DNA was iso-
lated from both normal lung tissue and tumor cells microdissected from lung pathological specimen. One of the alleles at both polymorphic
markers nearly disappeared in tumor cells (arrows). The upper bar with numerals shows an electrophoretic position of DNA fragment size (bases)
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